Natura Cosméticos S.A. (NATU3.SA) Investment Analysis

1. Executive Summary

This report provides a detailed investment analysis of Natura Cosméticos S.A., a Brazilian-based leader in the Latin American cosmetics, fragrances, and personal care (CFPC) market. The company, which now trades exclusively on the B3 exchange under the ticker NATU3.SA, is the result of a profound corporate simplification completed in mid-2025. This transformation involved the divestiture of its global assets—notably Aesop and The Body Shop —and the ongoing sale of Avon International operations.

The "new Natura" is a geographically focused pure-play on the Latin American market. Its business model is built upon a powerful, multi-channel, direct-to-consumer (D2C) framework that leverages two core brands: the premium, sustainability-focused 'Natura' brand and the mass-market, high-recognition 'Avon' brand. This model is activated by a network of over 3 million beauty consultants, a rapidly expanding e-commerce presence, and a physical footprint of over 1,000 stores.

The central investment thesis presented in this analysis is that Natura Cosméticos S.A. represents a significantly mispriced entity. The market's current valuation appears to be anchored to the company's complex, debt-laden, and operationally challenged past as a global holding company (Natura &Co Holding S.A., or NTCO3). This legacy valuation fails to recognize the radical simplification of the business structure and, more critically, the powerful margin expansion already evident in the financial results of the first half of 2025. These improved margins are a direct consequence of the "Wave 2" integration of its Natura and Avon operations in Latin America. The investment opportunity, therefore, lies in the market's eventual re-rating of NATU3.SA as a high-margin, cash-generative, and focused LatAm consumer staples leader.

2. Business Drivers & Strategic Overview

The "New Natura": A Deliberate Transformation

The entity trading as NATU3.SA today is fundamentally different from the one that existed 24 months ago. The company's prior iteration, Natura &Co Holding (NTCO3), was a complex, multi-brand global conglomerate that included Natura, Avon, The Body Shop, and Aesop. This global structure proved operationally unwieldy, accumulating significant debt and facing severe headwinds in disparate markets, ultimately obscuring the value of its core LatAm business.

In response, management executed a radical and decisive strategic simplification, beginning in 2023.

1. Sale of Aesop (2023): The first and most significant step was the sale of the high-growth, luxury brand Aesop to L'Oréal. This transaction provided a critical infusion of cash, enabling the company to pivot from a high-leverage position to a net cash balance by the end of 2023.

2. Sale of The Body Shop (2023): This was followed by the disposal of the chronically underperforming The Body Shop business , further streamlining operations and management focus.

3. Wind-Down of Avon International: The company is now in the final stages of exiting its ex-LatAm Avon business. These assets are classified as "held for sale". Recent announcements confirm this exit, including the sale of Avon's operations in Central America and the Dominican Republic (Avon CARD) and a binding agreement to sell the broader Avon International (Europe, Africa, Asia) business to Regent.

The final step in this transformation was a corporate simplification. On July 1, 2025, the parent holding company (Natura &Co Holding S.A., NTCO3) was formally merged into its primary operating subsidiary (Natura Cosméticos S.A.). The company now trades under the single, legacy ticker NATU3, which it used at its 2004 IPO.

This strategy is not a minor restructuring; it is a complete capitulation on the prior global conglomerate model. Natura has deliberately retrenched to its fortress market—Latin America—where it possesses deep, durable competitive advantages. This simplification eliminates the "conglomerate discount" that previously plagued the stock, removes the financial and operational drag from the non-performing international assets, and results in a financial-reporting structure that is significantly cleaner and easier to analyze.

Primary Revenue Driver: "Wave 2" Integration

With the company now focused solely on LatAm, its single most important business driver is the "Wave 2" integration. This is the internal designation for the complex operational and commercial integration of the Natura and Avon brands within Latin America.

The mechanism of "Wave 2" involves unifying the commercial model, optimizing logistics, and, most importantly, harmonizing the consultant networks. This allows a single beauty consultant to sell products from both the premium 'Natura' and mass-market 'Avon' portfolios, theoretically increasing consultant productivity and average order value.

This integration is not merely a plan; it is an engine that is already delivering proven results.

• Status: The integration is mature in key markets like Brazil, Peru, and Colombia. The rollout in Mexico was completed in May 2025, and the Argentina rollout began in July 2025. Management expects full LatAm completion by the end of 2025.

• Proven Results: The financial benefits are no longer theoretical. The company's Q1 2025 results explicitly cited a 90-basis-point gross margin expansion in countries where the "Wave 2" integration had been rolled out. This was reiterated in Q2 2025, where margin improvements were credited to "greater efficiency in markets where the integration with Avon is already more mature".

The success of "Wave 2" is the single most important variable for the company's future. Its success is already visible in the first-half 2025 financials, and the core investment thesis assumes the successful completion in Mexico and Argentina will provide the final uplift to a new, sustainable level of profitability.

Market Leadership & Competitive Landscape

Natura is the recognized leader in the beauty and personal care market in Latin America. This is a large and attractive market, valued at approximately $20.6 billion US dollars in 2023 and forecast to grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2030. The company's core 'Natura' brand is exceptionally strong, consistently "outperforming the market" in Brazil and gaining market share.

However, Natura does not operate in a vacuum. Its primary competitor is the private, formidable, and agile Grupo Boticário. This "battle of giants" narrative is a critical component of the risk analysis.

• Boticário's Scale: Grupo Boticário is a larger competitor. It reported total sales of R$ 35.7 billion in 2024, a 19% increase year-over-year.

• Natura's Scale: By comparison, Natura's 2024 consolidated net revenue (a "messy" figure including discontinued operations) was R$ 24.1 billion , while its LatAm-specific revenue grew 12.4% in constant currency.

This comparison suggests that while the 'Natura' brand is winning, the consolidated Natura entity may be ceding share to the faster-growing Boticário. This discrepancy is explained by the persistent "ongoing challenges still faced by the Avon brand". Therefore, the "Wave 2" integration is not just a margin-expansion story; it is a critical defensive strategy to stabilize the Avon brand and prevent further market share erosion to Boticário.

3. Financial Performance & Valuation

Historical Performance: The New Baseline (2024-2025)

Analyzing Natura's historical performance requires separating the "messy" 2024 baseline, which was heavily distorted by discontinued operations, from the "clean" 2025 results, which represent the new, focused LatAm entity.

Fiscal Year 2024 (The "Messy" Baseline): This year was characterized by complex accounting due to the divestments and deconsolidation of Avon Products Inc. (API).

• Net Revenue: R$ 24.1 billion

• Recurring EBITDA: R$ 2.9 billion

• Recurring EBITDA Margin: 12.2%

• Reported Net Loss: R$ 8.9 billion. This loss was almost entirely driven by a R$ 7.0 billion non-cash, non-recurring accounting loss from the API deconsolidation.

• Underlying Net Income: R$ 524 million

First Half 2025 (The "Clean" Baseline): This period provides the first clear, unambiguous view of the new, focused LatAm entity's financial power.

• Q1 2025 (LatAm): Net Revenue was R$ 5.3 billion, a 12.2% increase in constant currency versus Q1 2024. The recurring EBITDA margin was an exceptionally strong 15.0%.

• Q2 2025 (LatAm): Net Revenue was R$ 5.7 billion, up 5.5% in constant currency. The recurring EBITDA margin remained robust at 14.7%. The company reported Net Income (LatAm) of R$ 445 million for the quarter.

The most critical takeaway from this data is the margin divergence. The actual, reported recurring EBITDA margin for the new LatAm business in H1 2025 averaged 14.85%. This directly contradicts stale analyst forecasts, such as S&P Global's expectation of margins "slightly above 10% for 2025". This disconnect implies the market is using outdated models that have not incorporated the proven success of the "Wave 2" integration.

Key Metrics & Current Valuation

Based on the latest available financial data and market close on October 26, 2025, the company's valuation can be established.

• Current Share Price (NATU3.SA): R$ 8.74

• Market Capitalization: R$ 12.1 billion

• Net Debt (as of Q2 2025): R$ 3.989 billion

• Enterprise Value (EV): R$ 12.1B (Market Cap) + R$ 3.99B (Net Debt) = R$ 16.09B

To derive a meaningful valuation multiple, a Trailing Twelve Month (TTM) EBITDA for the "new" LatAm entity must be estimated from the "clean" H1 2025 results.

• H1 2025 LatAm Revenue: R$ 5.3B (Q1) + R$ 5.7B (Q2) = R$ 11.0B

• H1 2025 LatAm EBITDA: (R$ 5.3B 15.0% margin) + (R$ 5.7B 14.7% margin) = R$ 795M + R$ 838M = R$ 1.633B

• Annualized (H1*2) EBITDA Estimate: R$ 1.633B 2 = R$ 3.27B

This actuals-based figure of R$ 3.27B is used as the TTM EBITDA, as it is more current and proven than S&P's forecast of "EBITDA approaching R$3 billion in 2026".

Current Valuation Multiples:

• EV / TTM EBITDA: R$ 16.09B (EV) / R$ 3.27B (TTM EBITDA) = 4.92x

• P/E Ratio: Not Meaningful (N/M). Current P/E ratios are distorted by the massive non-cash restructuring charges from 2024, rendering them useless for analysis.

An EV/EBITDA multiple of approximately 4.9x is extraordinarily low for a market-leading consumer staples company with demonstrated 14.7%+ EBITDA margins, positive net income, and double-digit revenue growth (in Q1). Industry multiples for personal products are significantly higher. This discrepancy is the investment thesis. The market is pricing NATU3.SA at a distressed level, not as the high-margin, focused leader its latest results portray.

Table 1: Historical Financial Summary & Baseline Valuation (in BRL)

4. Risk Assessment & Macroeconomic Considerations

Despite the compelling financial transformation, significant risks persist. These are categorized into internal business risks and external macroeconomic headwinds.

Key Business Risks

1. Execution Risk (Wave 2): The success of the "Wave 2" integration is the central pillar of the bull thesis, but it is not yet complete. The company is still in the midst of its complex roll-out in Mexico and Argentina. A failed integration in these key markets could disrupt the consultant network, alienate customers, and reverse the critical margin gains achieved in the first half of 2025.

2. Competitive Risk (Grupo Boticário): As identified, Grupo Boticário is a larger, faster-growing, and highly effective private competitor. If Boticário continues its 19% growth trajectory, it will continue to take market share from the combined Natura/Avon entity. This implies Natura's strategy must not only deliver margins but also re-accelerate top-line growth.

3. Brand Revitalization Risk (Avon): The 'Natura' brand is strong, but company disclosures repeatedly cite the "ongoing challenges still faced by the Avon brand". There is a material risk that the Avon brand is in a state of terminal decline in Latin America and that no amount of integration can reverse this. If Avon fails, the synergies of "Wave 2" (which rely on both brands) would be temporary.

4. Cash Flow Inflection Risk: The company's financial health is contingent on a successful cash flow inflection. S&P Global forecasts that free operating cash flow (FOCF) will remain negative in 2025 and only turn positive in 2026, to over R$ 800 million. If this inflection fails to materialize—due to higher-than-expected restructuring costs, integration charges, or poor working capital management—the company's deleveraging story will collapse, and its current leverage ratio of 2.18x Net Debt/EBITDA could quickly become unmanageable.

Macroeconomic Environment (Brazil & LatAm)

The macroeconomic environment in Natura's core market provides a strong counter-argument to the H1 2025 outperformance and forms the basis for the "Low Case" scenario.

• Slowing Growth: The Brazilian economy is slowing down. Consensus forecasts call for GDP expansion of ~2.2% in 2025, slowing further to just 1.5% in 2026. This deceleration is a direct headwind for consumer discretionary spending, which has already shown signs of weakness.

• High Inflation & Interest Rates: Inflation remains persistent, recorded at 5.17% in September 2025. This has forced the Brazilian Central Bank to maintain a high policy interest rate, which is forecast to remain at 15% through 2025, with monetary easing not expected to begin until early 2026. High interest rates directly reduce the purchasing power of Natura's consumer base.

• FX Volatility: The BRL/USD exchange rate is a key variable. S&P forecasts an average of R5.80 for 2025-2026. While the "new Natura" is more insulated (with LatAm revenues and costs), significant BRL weakness increases the cost of imported raw materials for its products, potentially pressuring the gross margins that have been so critical to its recovery.

The macro environment presents a clear challenge. The bull case is that Natura is executing despite these headwinds, a sign of a high-quality, resilient company. The bear case is that the strong H1 2025 was a "last gasp" before the slowing consumer and high-rate environment cause revenue growth and margins to contract in the second half of 2025 and into 2026.

Table 2: Key Macroeconomic Forecasts (Brazil)

5. 5-Year Scenario Analysis (2026-2030)

This section presents a 5-year financial forecast for the restructured, LatAm-focused Natura Cosméticos S.A. The objective is to determine a fundamental value for the business based on detailed, sourced assumptions, independent of the current, depressed stock price. All figures are in Brazilian Reais (BRL).

Core Modeling Assumptions (Provenance)

The following inputs form the basis for all three scenarios.

• Year-End 2025 Revenue Base: R$ 25.74B. This is derived from Natura's 2024 LatAm revenue of R$ 23.4 billion , grown by S&P's 2025 LatAm growth forecast of 10%.

• Year-End 2025 EBITDA Base: R$ 3.82B. This is derived by applying the actual H1 2025 average recurring EBITDA margin of 14.85% to the 2025 revenue base. This model rejects the stale 10-11% margin forecasts in favor of the company's proven, reported results.

• Year-End 2025 Net Debt Base: R$ 3.99B. This is the last reported figure from Q2 2025.

• Market Growth (Baseline): The LatAm cosmetics market is forecast to grow at a 4.6% CAGR.

• Cash Flow: Free cash flow is assumed to be negative in 2025 but to inflect positively in 2026, per guidance.

• Terminal Multiple: The current 4.9x EV/EBITDA multiple is considered a "distress" valuation. The scenarios will exit on a multiple ranging from 5.0x (distress continues) to 13.0x (re-rated as a growth staple).

Table 3: 5-Year Financial Model Assumptions (2026E-2030E)

Base Case Scenario: "Successful Simplification"

• Probability: 50%

• Narrative & Fundamentals: This scenario assumes management executes its stated plan. The "Wave 2" integration is completed successfully by year-end 2025. The Avon brand stabilizes, and the 'Natura' brand continues its strong performance. The company successfully grows at a 6.0% CAGR, modestly outpacing the 4.6% market by leveraging its dual-brand network. The high 14.85% margin from H1 2025 proves sustainable and expands slightly to 15.5% by 2030 due to operating leverage. The company successfully deleverages, achieving its 2026 FCF target and paying down all debt.

• Detailed Financials (2026E-2030E):

  • 2030E Revenue: R$ 25.74B (2025 Base) = R$ 34.45B

  • 2030E EBITDA: R$ 34.45B (2030E Rev) 15.5% (Target Margin) = R$ 5.34B

  • 2030E Net Debt: R$ 3.99B (2025 Base) - R$ 4.0B (Cumulative Deleveraging) = ~R$ 0.0B

• Valuation (2030E):

  • Terminal EV/EBITDA Multiple: 10.0x. This is a reasonable multiple for a stable, market-leading, net-debt-free consumer staple.

  • 2030E Enterprise Value: R$ 5.34B (2030E EBITDA) 10.0x = R$ 53.4B

  • 2030E Equity Value: R$ 53.4B (EV) - R$ 0.0B (Net Debt) = R$ 53.4B

• Projected Share Price (2030E):

  • Implied Upside: R$ 53.4B (Target Equity) / R$ 12.1B (Current Equity) = 4.41x

  • 2030E Share Price: R$ 8.74 (Current Price) 4.41 = R$ 38.54

High Case Scenario: "Market Share Dominance"

• Probability: 25%

• Narrative & Fundamentals: "Wave 2" is a resounding success, creating a powerful competitive moat that allows Natura to take significant market share from its rival, Boticário. The Avon brand is fully revitalized and returns to growth. Margin expansion is significant as synergies accelerate, and FCF generation far exceeds the 2026 target. This allows for rapid deleveraging to a net cash position and significant capital returns. The market re-rates the stock as a best-in-class LatAm growth story.

• Detailed Financials (2026E-2030E):

  • 2030E Revenue: R$ 25.74B (2025 Base) = R$ 37.82B

  • 2030E EBITDA: R$ 37.82B (2030E Rev) 17.0% (Target Margin) = R$ 6.43B

  • 2030E Net Debt: R$ 3.99B (2025 Base) - R$ 6.0B (Cumulative Deleveraging) = ~R$ -2.0B (Net Cash)

• Valuation (2030E):

  • Terminal EV/EBITDA Multiple: 13.0x. This reflects its status as a high-growth, high-margin, net-cash industry leader.

  • 2030E Enterprise Value: R$ 6.43B (2030E EBITDA) 13.0x = R$ 83.59B

  • 2030E Equity Value: R$ 83.59B (EV) - (R$ -2.0B Net Cash) = R$ 85.59B

• Projected Share Price (2030E):

  • Implied Upside: R$ 85.59B (Target Equity) / R$ 12.1B (Current Equity) = 7.07x

  • 2030E Share Price: R$ 8.74 (Current Price) 7.07 = R$ 61.80

Low Case Scenario: "The Value Trap"

• Probability: 25%

• Narrative & Fundamentals: This is the conservative, bear-case scenario. The "Wave 2" integration in Mexico and Argentina falters. The Avon brand's "challenges" accelerate, becoming a permanent drain. The tough macroeconomic environment and fierce competition from Boticário lead to revenue stagnation and market share loss. Margins compress as the company is forced to discount, falling back to the 11.0% level forecasted by stale analyst reports. The 2026 FCF inflection never materializes, and the company is unable to meaningfully deleverage.

• Detailed Financials (2026E-2030E):

  • 2030E Revenue: R$ 25.74B (2025 Base) = R$ 28.42B (growing below inflation).

  • 2030E EBITDA: R$ 28.42B (2030E Rev) 11.0% (Target Margin) = R$ 3.13B

  • 2030E Net Debt: R$ 3.99B (2025 Base) - R$ 0.0B (Cumulative Deleveraging) = ~R$ 4.0B

• Valuation (2030E):

  • Terminal EV/EBITDA Multiple: 5.0x. The market confirms the stock is a "value trap," and the multiple remains near today's distressed level.

  • 2030E Enterprise Value: R$ 3.13B (2030E EBITDA) 5.0x = R$ 15.65B

  • 2030E Equity Value: R$ 15.65B (EV) - R$ 4.0B (Net Debt) = R$ 11.65B

• Projected Share Price (2030E):

  • Implied Upside: R$ 11.65B (Target Equity) / R$ 12.1B (Current Equity) = 0.96x

  • 2030E Share Price: R$ 8.74 (Current Price) 0.96 = R$ 8.41 (a negative total return).

Scenario Summary & Probability-Weighted Outcome

Table 4: 5-Year Share Price Trajectory (2025-2030)

Probability-Weighted 5-Year Price Target:

• (High Case: R$ 61.80 25.0% probability) = R$ 15.45

• (Base Case: R$ 38.54 50.0% probability) = R$ 19.27

• (Low Case: R$ 8.41 25.0% probability) = R$ 2.10

• Probability-Weighted 2030 Price Target = R$ 36.82

This analysis reveals a significant asymmetric risk/reward profile. The current share price of R$ 8.74 is already below the 5-year Low Case target of R$ 8.41. This implies the market is pricing in a scenario worse than the conservative "Value Trap" case. The probability-weighted outcome of R$ 36.82, which is fundamentally derived from the company's proven H1 2025 performance, suggests a potential upside of over 320% from the current price.

SIGNIFICANTLY MISPRICED

6. Qualitative Scorecard

This scorecard provides a subjective, narrative-driven assessment of key qualitative factors.

Table 5: Qualitative Scorecard

PROFITABLE, BUT UNPROVEN

7. Conclusion & Investment Thesis

The overall outlook for Natura Cosméticos S.A. is one of cautious, fundamental-driven optimism. The company has successfully navigated a near-existential crisis by shedding its complex and underperforming global assets. It has emerged as a leaner, simpler, and more focused entity, concentrated entirely on its high-margin, market-leading core in Latin America.

The investment thesis is a classic "post-restructuring" value play. The market is pricing NATU3.SA at a distressed 4.9x EV/EBITDA multiple (calculated), a valuation that reflects its "fallen angel" status and appears to be anchored on stale, pessimistic analyst forecasts. This valuation completely ignores the proven profitability of the new, simplified entity, which demonstrated a robust ~14.85% recurring EBITDA margin in the first half of 2025.

The primary catalysts for a re-rating of the stock are:

1. Positive FCF in 2026: The single most important catalyst will be the company's reporting of positive free cash flow, in line with S&P guidance. This will prove the new business model's sustainability and deleveraging capability.

2. Margin Stability: Delivering Q3 and Q4 2025 results that confirm the 14.7%+ EBITDA margin, proving that the H1 2025 performance was not an anomaly.

3. Analyst Re-ratings: As sell-side analysts are forced to update their "stale" models to reflect the new 14-15% margin reality, their price targets should rise, forcing a broader market re-evaluation.

The primary risks to this thesis remain:

1. Failed Integration: A fumble in the final "Wave 2" roll-out in Mexico and Argentina could reverse the margin gains.

2. Competitive Loss: An inability to stabilize the struggling Avon brand could lead to permanent market share loss to the larger and faster-growing Grupo Boticário.

The 5-year scenario analysis suggests a probability-weighted price target of R$ 36.82, representing a potential upside of over 320% from the current R$ 8.74 price. The fact that the current price is below the fundamentally-derived Low Case target of R$ 8.41 suggests a highly asymmetric risk/reward profile for long-term, fundamental-focused investors.

VALUE HIDING IN PLAIN SIGHT

8. Technical Analysis, Price Action & Short-Term Outlook

As of October 26, 2025, NATU3.SA is trading at R$ 8.74, which is alarmingly close to its 52-week low of R$ 8.06. The long-term trend is exceptionally weak, with a 1-year price change of -40.92%. Technical indicators on monthly and weekly charts signal a "Strong Sell," reflecting this severe downward momentum. While some very short-term (hourly/daily) indicators show "Buy" signals, the dominant technical picture is one of a deeply broken chart, trading far below its key long-term moving averages. This presents a classic conflict between bearish technicals and a (potentially) bullish fundamental turning point.

BROKEN CHART, FUNDAMENTAL BOTTOM?